Yarbrough Capital’s Cardiff Oncology CRDF Stock Holding History

Yarbrough Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-88,163	Closed	-$277K	–	162
2025 Q1	$277K	Buy	+88,163	New	+$349K	0.01%	176

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Yarbrough Capital's CRDF Position: Q2 2025 in Review

Yarbrough Capital sold out of Cardiff Oncology (CRDF) in Q2 2025, closing a stake of 88,163 shares — an estimated $277K sold.

Yarbrough Capital first reported a position in CRDF in Q1 2025 and held it in 1 quarter. The position peaked at $277K in Q1 2025. 114 funds tracked by Wall St. Rank hold CRDF as of Q2 2025.

Yarbrough Capital reported no remaining Cardiff Oncology position as of Q2 2025 after selling out during the quarter.
Yarbrough Capital sold 88,163 Cardiff Oncology shares in Q2 2025, an estimated $277K.
Yarbrough Capital first reported a position in Cardiff Oncology in Q1 2025 and held it in 1 quarter.
Yarbrough Capital's Cardiff Oncology position peaked at $277K in Q1 2025.
114 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2025.

Based on Yarbrough Capital's 13F filing for Q2 2025, filed 15 Jul 2025.